保妇康栓联合α-2a干扰素对宫颈高危型乳头瘤病毒持续性感染的临床研究

Clinical Study of Baofukang Suppository and α-2a Treatment of hr-HPV Persistent Infection

目的探讨保妇康栓联合重组人干扰素(α-2a)对持续性高危型乳头瘤病毒(hr-HPV)感染的治疗效果。方法回顾我院收入的60例hr-HPV持续性感染患者,随机分为两组。其中30例临床采取保妇康栓联合α-2a干扰素交替治疗,作为研究组,另外30例单独采取重组人干扰素(α-2a)进行治疗,作为对照组。比较两组患者治疗3个月、6个月后的显效率与不良反应发生情况,并比较不同亚型hr-HPV的治疗临床效果。结果 (1)研究组在3个月、6个月的显效率均高于对照组,对比具有差异性(P<0.05);(2)研究组患者的治疗并发率低于对照组,但是两组对比无明显差异,无统计学意义(P>0.05)。(3)研究组的HPV16、HPV18治疗效果均好于对照组,对比具有差异性(P<0.05),其他亚型对比无差异。结论临床上对于hr-HPV患者的持续性感染,采用保妇康栓联合重组人干扰素(α-2a)的疗效更稳定持久,而且能满足各种亚型HPV的治疗;因此,对于持续性hr-HPV感染患者,临床上应根据患者实际情况推广保妇康栓与重组人干扰素(α-2a)的交替治疗方案。

OBJECTIVE Investigated the clinical effect of Baofukang suppository and α-2a on hr-HPV persis- tent infection. METHODS Chosen 60 patients with hr-HPV and divided into two groups. The research group （30 cases） were treated with Baofukang suppository and α-2a, and the control group （30 cases ） were treated with α- 2a. Compared the effective rate and complications between the two groups after treatment for 3 months and 6 months,and compared the clinical effects of different subtypes of hr-HPV. RESULTS ①The effective rate of the research group at 3 months and 6 months was higher than that of the control group （ P 〈 0. 05 ）. ②The complication rate of the study group was lower than that of the control group, but there was no significant difference between the two groups （P 〉 0. 05 ）. ③The effect of HPV16 and HPV18 in the research group were significantly better than those in the con- trol group （ P 〈 0. 05 ）, but there was no difference in other subtypes （ P 〉 0. 05 ）. CONCLUSION Baofukang sup- pository and ct-2a treatment of hr-HPV were more stable and durable and could meet a variety of subtypes HPV.